Cellens Inc
Sensing Cancer on a Nanoscale Level
- Headquarters
- Boston, Massachusetts
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- cellensinc.com
- Total Funding
- $6.5M
- Last Round
- $6.5M SeedDec 2025
About
Cellens is a Boston-based Tufts University spinout pioneering a non-invasive cancer diagnostics platform that uses nanoscale mechanobiology and machine learning to detect bladder cancer from urine samples. Its Octosense platform scans cell surfaces at nanoscale resolution to identify unique biophysical fingerprints of cancer cells. The company raised a $6.5M seed round in December 2025 to advance its AI-driven diagnostic technology.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account